Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-19
2011-07-19
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S574000
Reexamination Certificate
active
07981908
ABSTRACT:
The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal.
REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4767627 (1988-08-01), Caldwell et al.
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 4853230 (1989-08-01), Lovgren et al.
patent: 5137729 (1992-08-01), Kuroya et al.
patent: 5238686 (1993-08-01), Eichel et al.
patent: 5559152 (1996-09-01), Komissarova et al.
patent: 5731002 (1998-03-01), Olovson et al.
patent: 5750531 (1998-05-01), Lee et al.
patent: 5800832 (1998-09-01), Tapolsky et al.
patent: 5840737 (1998-11-01), Phillips
patent: 6093738 (2000-07-01), Karimian et al.
patent: 6159498 (2000-12-01), Tapolsky et al.
patent: 6228400 (2001-05-01), Lee et al.
patent: 6296876 (2001-10-01), Odidi
patent: 6489346 (2002-12-01), Phillips
patent: 6645988 (2003-11-01), Phillips
patent: 6699885 (2004-03-01), Phillips
patent: 6780882 (2004-08-01), Phillips
patent: 6815414 (2004-11-01), Chowers et al.
patent: 7211568 (2007-05-01), Liu et al.
patent: 7271146 (2007-09-01), Glozman
patent: 2001/0020005 (2001-09-01), Chowers et al.
patent: 2003/0049204 (2003-03-01), Leyland-Jones
patent: 2004/0067875 (2004-04-01), Lai et al.
patent: 2004/0106634 (2004-06-01), Satoh et al.
patent: 2004/0248942 (2004-12-01), Hepburn
patent: 2005/0181052 (2005-08-01), Patel et al.
patent: 2005/0232992 (2005-10-01), Devane et al.
patent: 2005/0239845 (2005-10-01), Proehl et al.
patent: 2006/0135406 (2006-06-01), Glozman et al.
patent: 2006/0257467 (2006-11-01), Kostadinov et al.
patent: 05129 (1979-10-01), None
patent: 124495 (1984-11-01), None
patent: 166287 (1986-01-01), None
patent: 174726 (1986-03-01), None
patent: 259174 (1988-03-01), None
patent: 322133 (1989-06-01), None
patent: 404322 (1990-12-01), None
patent: 1 087 783 (2001-04-01), None
patent: 1917959 (2008-05-01), None
patent: 07804623 (2009-10-01), None
patent: 2163747 (1986-03-01), None
patent: 2 394 895 (2004-05-01), None
patent: 2240110 (2004-11-01), None
patent: WO-9006925 (1990-06-01), None
patent: WO-9119711 (1991-12-01), None
patent: WO-9119712 (1991-12-01), None
patent: WO 94/01099 (1994-01-01), None
patent: WO-9427988 (1994-12-01), None
patent: WO-9501977 (1995-01-01), None
patent: WO-9725030 (1997-07-01), None
patent: WO 99/65513 (1999-12-01), None
patent: WO-0078293 (2000-12-01), None
patent: WO 01/22985 (2001-04-01), None
patent: WO-0151050 (2001-07-01), None
patent: WO 2005/065664 (2005-07-01), None
patent: WO-2006120500 (2006-11-01), None
patent: WO-2008012621 (2008-01-01), None
European Examination Report, Application No. 07804623.2 Feb. 9, 2010.
International Search Report from PCT/IB2009/006176 dated Dec. 8, 2009.
Chand et al., “Sleep dysfunction in patients with gastro-oesophageal reflux disease: prevalence and response to GERD therapy, a pilot study”,Aliment Pharmacol. Ther. 2004, 20:969-974 (2004).
Chen et al., “Sleep Symptoms and Gastroesophageal Reflux”,J. Clin. Gastroenterol., 42(1):13-17 (2008).
Hatlebakk et al., “Pharmacokinetic Optimisation in the Treatment of Gastro-Oesophageal Reflux Disease”,Clin. Pharmacokinet., 31(5):386-406 (1996).
International Search Report for PCT/IB07/01078 dated Apr. 9, 2009.
International Search Report for PCT/IB05/02223 dated Mar. 28, 2006.
Morii et al., “The Potency of Substituted Benzimidazoles such as E3810, Omeprazole, Ro 18-5364 to Inhibit Gastric H+,K+-ATPase is Correlated with the Rate of Acid-Activation of the Inhibitor”,Biochem. Pharmacol., 39(4):661-667 (1990).
Sachs, G., “Improving on PPI-based therapy of GORD”,Eur. J. Gastroenterol. Hepatol., 13(Suppl. 1):S35-S41(2001).
Scarpignato et al., “Acid Suppression Therapy: Where Do We Go from Here?”Dig. Dis., 24:11-46 (2006).
Shaker et al., “Nighttime Heartburn Is an Under-Appreciated Clinical Problem That Impacts Sleep and Daytime Function: The Results of a Gallup Survey Conducted on Behalf of the American Gastroenterological Association”,Am. J. Gastroenterol., 98(7):1487-1493 (2003).
Tytgat, G.N., “Shortcomings of the first-generation proton pump inhibitors”,Eur. J. Gastroenterol. Hepatol., 13(Suppl. 1):S29-S33 (2001).
Written Opinion of the International Search Authority for PCTIB05/02223 dated Mar. 28, 2006.
Written Opinion of the International Search Authority for PCT/IB07/01078 dated Apr. 9, 2009.
Yau et al., “A comparison of omeprazole and ranitidine for prophylaxis against aspiration pneumonitis in emergency Caesarean section”,Anaesthesia, 47:101-104 (1992).
Ammar, D. A., et al., “Syntaxin 3 is required for camp-induced acid secretion: streptolysin O-permeabilized gastric gland model,”American Journal of Physiology—Gastrointestinal and Liver Physiology, 282:G23-G33 (2002).
Ayalon, A. et al., “Does Luminal Gastrin Stimulate Gastric Acid Secretion?”Am. J. Surg., 141:94-97 (1981).
De Graef, J. et al., “Influence of the Stimulation State of the Parietal Cells on the Inhibitory Effect of Omeprazole on Gastric Acid Secretion in Dogs,”Gastroenterology, 91:333-337 (1985).
Fiddian-Green, R.G. et al., “A physiological role for luminal gastrin?”Surgery, 83(6):663-668 (1978).
Hunt, J. N. et al., “The Effect of Citric Acid and Its Sodium Salts in Test Meals on the Gastric Outputs of Acid and of Chloride,”J. Physiol., 230(1):171-184 (1973).
Kuroda et al., “Inhibitory Effect of Fumaric Acid and Dicarboxylic Acids on Gastric Ulceration in Rats”,Arch. Int. Pharmacodyn., 226:324-330 (1977).
Maliuk et al, “Effect of Succinate Sodium on the Acid Forming and Motor Function of the Stomach in Patients with Tuberculosis”,rachebnoe Delo, 10:60-62 (1981). Summary Only.
Morrell, M. T. et al., “Absorption of Pentagastrin from Gastrointestinal Tract in Man,”Lancet, 2(7937):712 (1975).
Nagata et al., “Inhibitory Action of Lansoprazole and Its Analogs AgainstHelicobacter pylori: Inhibition of Growth is Not Related to Inhibition of Urease,”Antimicrobial Agents and Chemotherapy, 39(2):567-570 (1995).
Nobuhara et al., “Vinegar is a Dietary Mild Irritant to the Rat Gastric Mucosa”,Japanese Journal of Pharmacology, 41:101-108 (1986).
Pokrovsky, A. A. et al., “On the Role of Succinate in Energy Supply of the Hydrochloric Acid Secretion in the Gastric Mucosa”,Journal of Physiology, 10:1567-1573 (1973). Abstract Only.
Teyssen et al., “Maleic and Succinic Acid as Stimulants of Acid Production in Isolated Native Rat Gastric Parietal Cells”,Esophageal, Gastric and Duodenal Disorders, G1456:A333 (Apr. 1999).
Teyssen, S. et al., “Maleic Acid and Succinic Acid in Fermented Alcoholic Beverages Are the Stimulants of Gastric Acid Secretion,”The Journal of Clinical Investigation, 103(5):707-713 (1999).
Merritt, A.M., “The Equine Stomach: A Personal Perspective (1963-2003)”, 49thAnnual Convention of the American Association of Equine Practitioners, www.ivis.org, Nov. 21, 2003.
Atarot Tal
Ayelet David
Glozman Sabina
Kostadinov Aleksey
Elrifi Ivor R.
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Spivack Phyllis G.
Stock, Esq. Christina K.
Vecta Ltd.
LandOfFree
Compositions and methods for inhibiting gastric acid secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting gastric acid secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting gastric acid secretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2699877